Mundipharma Gets Further CHMP Pegfilgrastim Nod
The Firm’s Pelmeg Version Is Already Marketed In Europe
Executive Summary
Mundipharma has received a positive opinion from the CHMP for its pegfilgrastim biosimilar. However, the firm would not be drawn on how this version fits into its strategy, given that it already markets its Pelmeg version that it obtained through its acquisition of Cinfa Biotech last year.